文献速递前列腺癌

局限性前列腺癌局灶治疗五年更新系统综述:有哪些变化?

An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?
PubMed 文献 · Eur Urol · 2021-09-04

多数为前瞻性2a期单臂研究,HIFU和PDT进入3期并显示良好功能与肿瘤学结果,但高质量证据仍不足。

要点

  • 局灶治疗研究涵盖8种能量源,多数仍为2a期单臂研究。
  • HIFU研究显示中位95%患者无尿垫、中位85%治疗区无临床显著癌。
  • PDT未报告控尿变化,中位90%患者无临床显著癌。

核心结论

  • 过去5年局灶治疗研究覆盖8种能量源,但多数仍处于早期单臂研究阶段。
  • HIFU和PDT进入3期研究并显示良好功能与肿瘤学结果,但仍需高质量随机对照试验验证。

研究设计与样本

  • 共纳入5827例接受局灶治疗的局限性前列腺癌患者,按IDEAL推荐评估研究阶段。

主要发现

  • 多数研究为前瞻性2a期发展研究(n=357)。
  • HIFU研究中位95%患者无尿垫,中位85%患者治疗区无临床显著癌。
  • PDT未报告控尿变化,中位90%患者无临床显著癌,两者耐受性良好。

关键数值与推荐

  • HIFU:中位95%患者无尿垫,中位85%患者治疗区无临床显著癌。
  • PDT:未报告控尿变化,中位90%患者无临床显著癌。

临床怎么用

  • 局灶治疗对控尿和性功能影响小于根治性治疗,但当前证据多来自早期单臂研究。
  • HIFU和PDT显示较好结果,但尚不能作为标准治疗,需更多高质量随机对照试验。

局限性

  • 多数研究为单臂2a期研究,高质量评估不足。
  • 需多中心随机对照试验、长期随访及预设的肿瘤学、功能和生活质量评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Focal therapy is a promising, minimally invasive strategy to selectively treat localized prostate cancer. A previous systematic review indicated that there is growing evidence for favorable functional outcomes, but that oncological effectiveness was yet to be defined. OBJECTIVE: To assess the effectiveness of focal therapy in patients with localized prostate cancer in terms of functional and oncological outcomes. EVIDENCE ACQUISITION: PubMed, Embase, and The Cochrane Library were searched for studies between October 2015 and December 31, 2020. In addition, the research stages were acquired according to the Idea, Development, Exploration, Assessment, Long-term study (IDEAL) recommendations. Ongoing studies were identified through clinical trial registries. EVIDENCE SYNTHESIS: Seventy-two studies were identified exploring eight different sources of energy to deliver focal therapy in 5827 patients. Twenty-seven studies reported on high-intensity focused ultrasound (HIFU), nine studies on irreversible electroporation, 11 on cryoablation, eight on focal laser ablation and focal brachytherapy, seven on photodynamic therapy (PDT), two on radiofrequency ablation, and one on prostatic artery embolization. The majority of studies were prospective development stage 2a studies (n = 357). PDT and HIFU, both in stage 3, showed promising results. Overall, HIFU studies reported a median of 95% pad-free patients and a median of 85% patients with no clinically significant cancer (CSC) in the treated area. For PDT, no changes in continence were reported and a median of 90% of patients were without CSC. Both treatments were well tolerated. CONCLUSIONS: Over the past 5 yr, focal therapy has been studied for eight different energy sources, mostly in single-arm stage 2 studies. Although a first randomized controlled trial in focal therapy has been performed, more high-quality evaluations are needed, preferably via multicenter randomized controlled trials with long-term follow-up and predefined assessment of oncological and functional outcomes and health-related quality-of-life measures. PATIENT SUMMARY: Focal treatment (FT) of prostate cancer has potential, considering that it has less impact on continence and potency than radical treatment. Our systematic review indicates that despite the method being studied extensively over the past half decade, the majority of studies remain in an early research stage. The techniques high-intensity focused ultrasound and photodynamic therapy have shown most progression toward advanced research stages and show favorable results. However, more high-quality evidence is required before FT can become available as a standard treatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Hopstaken JS, Bomers JGR, Sedelaar MJP, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol. 2021. PMID: 34489140. doi:10.1016/j.eururo.2021.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。